tradmap

MAZE Earnings Maze Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$3 -$1 $1 $0 2024 2025
EPS
Revenue (annual)
$0 $84M $168M 2024 2025
Revenue
Net income (annual)
-$131M -$39M $52M $0 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$14 -$5 $3 $0 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Revenue (quarterly)
$0 $83M $165M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue
Net income (quarterly)
-$45M $47M $139M $0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
Net income

Reported EPS history

1–10 of 10
Q2 20262026-06-30-1.222026-08-1110-Q
Q1 20262026-03-31-0.452026-05-1210-Q
FY 20252025-12-31-3.052026-03-2510-K
Q3 20252025-09-30-2.452025-11-0610-Q
Q2 20262025-06-30-1.832026-08-1110-Q
Q1 20262025-03-31-1.152026-05-1210-Q
FY 20252024-12-311.252026-03-2510-K
Q3 20252024-09-302.672025-11-0610-Q
Q2 20252024-06-303.182025-08-1210-Q
Q1 20252024-03-31-13.912025-05-1410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.